This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Tasisulam

Eli Lilly & Company

Drug Names(s): LY573636-sodium

Description: LY573636 is an Acyl sulfonamide anti-proliferative agent (ASAP). Tasisulam was shown in initial screens to exhibit activity against a broad range of cancer cell lines, including melanoma. Tasisulam induces apoptosis via activation of the mitochondrialcell death pathway, which leads to cytochrome C release, caspases 2/9 activation, and ultimately apoptosis.Moreover, tasisulam-mediated mitochondrial dysfunction has been associated with decreased adenosinetriphosphate (ATP) production and increased levels of ROS within cancer cells.


Tasisulam News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug